Peripheral Neuropathy Research and Clinical Trials
Clinical trials are studies designed to find new and better ways to treat patients with neuropathy. The physicians at the Maryland Peripheral Neuropathy Center are currently conducting the clinical trials listed below.
For more information on our studies, please contact either
Improving Autonomic Function and Balance in Diabetic Neuropathy (IMABIN STUDY)
For more about the study, visit the study's page on clinicaltrials.gov.
Metabolic Syndrome and Fall Risk
The purpose of this project is to see if an exercise program can reduce fall risk in people with the metabolic syndrome (MetS) and autonomic neuropathy. The MetS is a set of risk factors for heart disease and diabetes that includes fat in the stomach area, high blood pressure, high cholesterol, and high blood sugar. The autonomic nervous system helps to control heart rate and blood pressure. Neuropathy is any disease of the peripheral nerves.
Learn more about this study on the clinicaltrials.gov page.
The validation of the CAP-PRI (chronic acquired polyneuropathy-patient reported index) in patients with acquired and idiopathic polyneuropathy
The CAP-PRI is a quality of life (QoL) measure that was recently generated and validated in a population of patients with chronic immune-mediated polyneuropathies (CIP) including chronic
inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), monoclonal gammopathy of undetermined significance (MGUS)-associated demyelinating polyneuropathy, and distal acquired demyelinating symmetric neuropathy (DADS).
Initially a 20-item instrument was generated from patient input and expert opinion. The 20-item instrument was rigorously studied with both modern and conventional psychometric analysis. It demonstrated excellent correlation with the Rasch Overall Disability Sum Score (R-ODS), INCAT disability scale, RAND-36, and Neuropathy Impairment Scale. It was then modified to the current 15-item measure with 3 response categories.
The 15-item CAP-PRI was recently validated in 39 subjects with CIP. At present there is no universally accepted QoL instrument used in clinical trials for patients with acquired polyneuropathies. Most QoL measures are generic and fail to capture relevant, disease-specific information.
Neuromuscular disorders, such as neuropathy, motor neuron disease and myopathy are common neurologic disorders that cause significant morbidity in the population. Establishing a database consisting of clinical information such as patient reported symptoms and clinician findings on physical exam facilitates further understanding of neuromuscular disorders.